MCW Pharmaceuticals is a subsidiary of Global Cancer Technology, Inc that has Intellectual Property to a technology that can treat cancer tumors so that they are more completely destroyed when radiation or chemotherapy is applied to the tumor
This technology is a notably promising anticancer compound is 7-hydroxy staurosporine, termed UCN-01, a potent staurosporine analog anti-tumor agent that is approved for patient testing, and is a superior radiochemotherapy sensitizer. UCN-01 even in non-cytotoxic doses markedly sensitizes tumor cells to radiation and chemotherapeutics, a characteristic that has led to over 400 papers and 22 NIH sponsored UCN-01 Phase I- III patient trials. However, a serious drawback of UCN-01 that has stymied its preclinical development is that it avidly binds the human plasma protein AAG, leaving the insufficient free (active) compound. Hence we were motivated to pursue reformulation via structural modification (pegylation) to avoid plasma proteins. So the pegylation prevents binding to AAG and thus the UCN-01, which is still active, can enter tumors. Pegylated UCN- 01 is expected to have much improved PK and bioavailability and potential for clinical success. Simply put, pegylation prevents UCN-01 from binding to plasma proteins but does not impede its pharmacological and pharmacodynamic behavior.